Criterium Expands to Canada
CRITERIUM, Inc. Global CRO Expands Services to Canada
Criterium, Inc., a full-service CRO is pleased to announce its newest global office located in Toronto!
Get to know us and let us give you a brief overview of Criterium's expertise and our abilities to successfully manage your clinical trials and data monitoring needs.
We all know resources are precious, time is the enemy, and results are paramount. Our user-friendly technologies are integrated into all aspects of our clinical development services for improved efficiencies. We have a talented in-house staff that is committed to the professional support of our clients' individual and particular needs and underpins our processes for maximum outcomes.
See videocast on Criterium's Web site: http://www.criteriuminc.com
Through our Phase I-IV trial experience in 20 different therapeutic areas in many regions of the world-including the USA, Central & Eastern Europe, Mexico, South America, Asia-Pacific, India, and South Africa-we have developed best practices to make sure we deliver the highest-quality results on time and on budget for our clients. We stand by this credo for each and every one of our clients.
As part of our full-service capabilities, we believe our unique approach to managing all aspects of the core asset of any clinical study-the data-is just one of the many factors that sets our teams of monitoring experts apart. We recognize the two major areas that most affect the workflow of clinical studies: how quickly the data come in and what happens with that information when it does arrive. To overcome these challenges, we changed the workflow paradigm by paying more attention to these data sets as they become available.
We welcome the opportunity to discuss our many services with you. Let us monitor your data and/or trials and experience the real difference we can create.
At Criterium who we are, what we do, and how we do it are centered on our service reputation: an uncompromising "always deliver" attitude in everything we do.
To mark the occasion we are offering new and existing clients a 15% discount on all services related to the Canadian market.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
